Table 2 A summary of clinical outcomes
From: Critical evaluation of stents in coronary angioplasty: a systematic review
Study | Stent type | No. of Ps | In-stent thrombosis | In-stent restenosis | TVR (%) | Anti-coagulation protocol |
|---|---|---|---|---|---|---|
[24] | BRS | 60 | 1 | 0 | 1.7 | Not given |
[25] | BRS | – | – | – | – | Not given |
[26] | DES | – | 15 | 0 | – | Not given |
[27] | BRS | 90 | 2 | 0 | – | Clopidogrel, prasugrel, ticagrelor |
[28] | PES | – | – | – | – | Clopidogrel (75 mg) for 12 months |
[29] | BMS | 32 | – | – | – | Clopidogrel (75 mg) for 12 months |
PES | 93 | – | – | – | ||
[30] | PES | 30 | 0 | 0 | – | Clopidogrel (75 mg) for 12 months |
[31] | BES | 369 | 6 | – | – | DAPT for 12 months |
EES | 1178 | 13 | – | – | ||
[23] | SES | 1261 | 5 | – | 4.1 | DAPT for 12 months |
BES | 1264 | 15 | – | 5.2 | ||
[32] | BES | 765 | 2 | – | 5.0 | Prasugrel for 12 months |
EES | 765 | 5 | – | 4.7 | ||
BMS | 761 | 5 | – | 10.4 | ||
[33] | DES | 958 | 4 | 9 | – | DAPT for 12 months |
ZES | 961 | 6 | 7 | – | ||
[34] | EES | 846 | 3 | – | 3.8 | DAPT for 12 months |
EES | 838 | 5 | – | 3.6 | ||
[35] | DES | 82 | – | 82 | – | Not given |
[36] | SES | 32 | – | – | – | Not given |
[37] | SES | 250 | – | 17 | 7.2 | Clopidogrel (75 mg) for 12 months |
BMS | 250 | – | 52 | 18.8 | ||
[38] | BRS | – | – | – | – | Not given |
[39] | BMS | 222 | 1 | – | 9.5 | Clopidogrel (75 mg) |
PES | 161 | 1 | – | 1.9 | ||
[40] | SES | 41 | 0 | 4 | 26.7 | Clopidogrel (75Â mg) for 6Â months |
PES | 41 | 0 | 15 | 8.7 | ||
[21] | BRS | 184 | 0 | – | 5.2 | DAPT for 6 months (minimum) |
[22] | BRS | 1296 | 9 | – | 4 | DAPT for 1 year (minimum) |